Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1

4 Apr 2013

Abstract excerpt

Lung cancer is still the leading cause of cancer-related deaths worldwide. Identifying new oncogenic drivers and developing efficient inhibitors through molecular targeting approaches are crucial for improving therapies. The aim of this study was to investigate whether targeting fibroblast growth factor receptor 1 (FGFR1) with ponatinib inhibits the cell growth in both established and primary lung cancer cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Fibroblast Growth Factor Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23563700
DOI: 10.3892/or.2013.2386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1PMID 23563700Read ↗

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCCSemantic proximity Read ↗

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Semantic proximity Read ↗

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Semantic proximity Read ↗

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer HistologiesSemantic proximity Read ↗

Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.Semantic proximity Read ↗

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung CancerSemantic proximity Read ↗

Role of FGF Receptors as an Emerging Therapeutic Target in Lung Squamous Cell CarcinomaSemantic proximity Read ↗

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Semantic proximity Read ↗

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancerSemantic proximity Read ↗

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacySemantic proximity Read ↗

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung CancerSemantic proximity Read ↗

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.